K K Doheny1, C Palmer, K N Browning, P Jairath, D Liao, F He, R A Travagli. 1. Department of Pediatrics, College of Medicine, Pennsylvania State University, Hershey, PA, USA; Division of Newborn Medicine, Penn State Children's Hospital, Hershey, PA, USA.
Abstract
BACKGROUND: Necrotizing enterocolitis (NEC) is an acute neonatal inflammatory disease which may lead to intestinal necrosis, multisystem failure, and death. Currently, NEC is diagnosed by a combination of laboratory and radiographic tests conducted a posteriori i.e., when NEC is already clinically significant. Given the acute onset and rapid progression of NEC, a non-invasive biomarker that allows early detection of patients at risk is required as a matter of urgency. We evaluated whether the high frequency (HF) component of heart rate variability (HRV), a measure of vagal efferent tonic cholinergic activity may be used as a predictive biomarker for NEC-risk before the onset of clinical disease. METHODS: In this prospective study, stable preterm (gestational age 28-35 weeks) infants had HRV power spectra analyzed from surface electrocardiogram waveforms taken at rest on day 5-8 of life. We used regression modeling to determine the utility of HF-HRV in predicting NEC. KEY RESULTS: HF-HRV power was 21.5 ± 2.7 and 3.9 ± 0.81 ms(2) in infants that remained healthy and those that later developed stage 2+ NEC, respectively (p < 0.001). Nine of 70 enrolled infants developed NEC. The ROC discriminated a HF-HRV value of 4.68 ms(2) predictive for developing NEC with a sensitivity and specificity of 89% and 87%, and positive and negative predictive value of 50% and 98%, respectively. With predictive regression modeling, the risk (odds ratio) of developing NEC was 10 per every one SD decrease in HF-HRV. CONCLUSIONS & INFERENCES: Our preliminary data indicate that HF-HRV may serve as a potential, non-invasive predictive biomarker of NEC-risk in NICU infants.
BACKGROUND:Necrotizing enterocolitis (NEC) is an acute neonatal inflammatory disease which may lead to intestinal necrosis, multisystem failure, and death. Currently, NEC is diagnosed by a combination of laboratory and radiographic tests conducted a posteriori i.e., when NEC is already clinically significant. Given the acute onset and rapid progression of NEC, a non-invasive biomarker that allows early detection of patients at risk is required as a matter of urgency. We evaluated whether the high frequency (HF) component of heart rate variability (HRV), a measure of vagal efferent tonic cholinergic activity may be used as a predictive biomarker for NEC-risk before the onset of clinical disease. METHODS: In this prospective study, stable preterm (gestational age 28-35 weeks) infants had HRV power spectra analyzed from surface electrocardiogram waveforms taken at rest on day 5-8 of life. We used regression modeling to determine the utility of HF-HRV in predicting NEC. KEY RESULTS: HF-HRV power was 21.5 ± 2.7 and 3.9 ± 0.81 ms(2) in infants that remained healthy and those that later developed stage 2+ NEC, respectively (p < 0.001). Nine of 70 enrolled infants developed NEC. The ROC discriminated a HF-HRV value of 4.68 ms(2) predictive for developing NEC with a sensitivity and specificity of 89% and 87%, and positive and negative predictive value of 50% and 98%, respectively. With predictive regression modeling, the risk (odds ratio) of developing NEC was 10 per every one SD decrease in HF-HRV. CONCLUSIONS & INFERENCES: Our preliminary data indicate that HF-HRV may serve as a potential, non-invasive predictive biomarker of NEC-risk in NICU infants.
Authors: Martin L Blakely; Kevin P Lally; Scott McDonald; Rebeccah L Brown; Douglas C Barnhart; Richard R Ricketts; W Raleigh Thompson; L R Scherer; Michael D Klein; Robert W Letton; Walter J Chwals; Robert J Touloukian; Arlett G Kurkchubasche; Michael A Skinner; R Lawrence Moss; Mary L Hilfiker Journal: Ann Surg Date: 2005-06 Impact factor: 12.969
Authors: Karen D Fairchild; Varadamurthy Srinivasan; J Randall Moorman; Ronald P A Gaykema; Lisa E Goehler Journal: Am J Physiol Regul Integr Comp Physiol Date: 2010-11-10 Impact factor: 3.619
Authors: Andrea Bravi; Geoffrey Green; Christophe Herry; Heather E Wright; André Longtin; Glen P Kenny; Andrew J E Seely Journal: Front Physiol Date: 2013-07-30 Impact factor: 4.566
Authors: Thomas Benkoe; Suzann Baumann; Manfred Weninger; Mario Pones; Carlos Reck; Winfried Rebhandl; Rudolf Oehler Journal: PLoS One Date: 2013-03-05 Impact factor: 3.240
Authors: M L Stone; P M Tatum; J-H Weitkamp; A B Mukherjee; J Attridge; E D McGahren; B M Rodgers; D E Lake; J R Moorman; K D Fairchild Journal: J Perinatol Date: 2013-05-30 Impact factor: 2.521
Authors: B A Sullivan; A Wallman-Stokes; J Isler; R Sahni; J R Moorman; K D Fairchild; D E Lake Journal: Am J Perinatol Date: 2018-05-28 Impact factor: 1.862
Authors: Brynne A Sullivan; Christina McClure; Jamie Hicks; Douglas E Lake; J Randall Moorman; Karen D Fairchild Journal: J Pediatr Date: 2016-04-22 Impact factor: 4.406
Authors: Alissa L Meister; Cameron R Burkholder; Kim K Doheny; R Alberto Travagli Journal: Neurogastroenterol Motil Date: 2019-08-06 Impact factor: 3.598
Authors: Fumiyuki C Gardner; Cherie S Adkins; Sarah E Hart; R Alberto Travagli; Kim Kopenhaver Doheny Journal: Adv Neonatal Care Date: 2018-02 Impact factor: 1.968
Authors: Madeline L Keyes; Helen Healy; Katherine A Sparger; Lucas E Orth; Mayya Geha; Sergei Roumiantsev; Juan D Matute Journal: Pediatrics Date: 2021-02 Impact factor: 7.124